^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    idarubicin hydrochloride

    i
    Other names: IDA, DMDR, FCE 22723, IMI 30, NSC 256439
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor, DNA cross linking agent
    Related drugs:
    3d
    NCI-2019-08626: BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date • Tumor mutational burden
    |
    Keytruda (pembrolizumab) • cytarabine • daunorubicin • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)
    15d
    NCI-2023-03572: Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms (clinicaltrials.gov)
    P1, N=30, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2027 --> Dec 2029
    Trial completion date
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Chr t(15;17)
    |
    cytarabine • idarubicin hydrochloride • fludarabine IV • pivekimab sunirine (PVEK) • Starasid (cytarabine ocfosfate)
    17d
    Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P3, N=158, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2025 --> Jun 2029
    Trial completion date
    |
    RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
    |
    cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    18d
    IntReALL BCP 2020 International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 (2023-509392-17-00)
    P2/3, N=765, Not yet recruiting, Charite Universitaetsmedizin Berlin KR
    New P2/3 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    |
    cytarabine • Blincyto (blinatumomab) • etoposide IV • Besponsa (inotuzumab ozogamicin) • vincristine • idarubicin hydrochloride • mitoxantrone • mercaptopurine • vindesine
    18d
    SNDX-5613-0710: Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML (2025-522279-27-00)
    P2/3, N=239, Not yet recruiting, Syndax Pharmaceuticals Inc.
    New P2/3 trial
    |
    NPM1 (Nucleophosmin 1)
    |
    NPM1 mutation
    |
    cytarabine • daunorubicin • Revuforj (revumenib) • idarubicin hydrochloride
    22d
    CR109124: A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies (clinicaltrials.gov)
    P1, N=196, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • NUP214 (Nucleoporin 214)
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • idarubicin hydrochloride • bleximenib (JNJ-6617)
    22d
    VAG-3+7-G: VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P3 trial
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3-TKD mutation
    |
    Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine • daunorubicin • idarubicin hydrochloride
    24d
    A Rare Case of Acute Promyelocytic Leukemia with ider(17)(q10)t(15;17)(q22;q21) and FLT3-ITD Mutation. (PubMed, Clin Lab)
    This case of APL with coexisting ider(17) and FLT3-ITD mutations exhibited an aggressive course and resistance to standard treatment. These findings suggest that such patients may require intensified therapeutic strategies and closer monitoring.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • Chr t(15;17)
    |
    idarubicin hydrochloride
    26d
    Refractory Clinical Course of Acute Myeloid Leukemia With t(8; 10; 21)(q22; q22; q22.1): A Case Report and Literature Review of This Variant Form. (PubMed, Cureus)
    After being diagnosed with AML with t(8;10;21)(q22;q22;q22.1), he received standard induction therapy consisting of cytarabine for seven days and idarubicin for three days, but failed to achieve remission. Reinduction and salvage therapies were also ineffective. This variant form may be associated with a lower likelihood of achieving complete remission (CR) after initial induction therapy. Failure to achieve CR after initial induction therapy in AML is an adverse prognostic factor; therefore, the presence of t(8;21)/RUNX1::RUNX1T1 with three-way translocations may warrant consideration of hematopoietic stem cell transplantation at an earlier stage in the treatment course.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)
    |
    cytarabine • idarubicin hydrochloride
    1m
    Myeloid sarcoma transformed from myeloproliferative neoplasm: A case report and review of literature. (PubMed, World J Clin Oncol)
    Cases of myelofibrosis transforming into MS are extremely rare. The TP53 mutation is a key molecular marker associated with poor tumor prognosis. Because it can be easily mistaken for other tumors, it is crucial to perform relevant examinations and establish a clear diagnosis as early as possible. This facilitates the timely formulation of an appropriate treatment plan and may help prolong the patient's life.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • cytarabine • Jakafi (ruxolitinib) • idarubicin hydrochloride
    1m
    AML16: A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=206, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Jun 2025 --> Sep 2025
    Trial primary completion date
    |
    sorafenib • azacitidine • etoposide IV • decitabine • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neupogen (filgrastim) • dexrazoxane
    1m
    Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=102, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • cytarabine • daunorubicin • idarubicin hydrochloride • fludarabine IV • Starasid (cytarabine ocfosfate)